Cardinal Health, Inc.

As of June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh carries a market capitalization of 283.07B, placing it among publicly traded companies globally. Its enterprise value stands at 304.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh has 233.28M shares outstanding.

As of June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh trades at a trailing price-to-earnings ratio of 32.33. The price-to-sales ratio is 0.22, and the price-to-book ratio stands at -19.00.

As of June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh trades at an EV/EBITDA multiple of 16.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.56 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh trades at an EV/FCF ratio of 12.29, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 304.73B versus a market cap of 283.07B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -326.21, indicating conservative leverage, while an interest coverage ratio of 10.26 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on invested capital (ROIC) comes in at 35.21 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.10, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 33.11, useful for judging operating efficiency across full business cycles. The company generates approximately 22.18M in revenue per employee across its workforce of 59,250.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 14.33 indicates how many times Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh recorded 2.42B in income tax expense. That works out to an effective tax rate of 21.57, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.24B, leaving 8.86B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 21, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh's stock has gained approximately 58.93% over the past 52 weeks. The 50-day moving average sits at 1,210.77, while the 200-day moving average is 1,001.79.

Over the twelve months ended June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh generated 1.31T in revenue and converted that into 8.86B in net income, yielding earnings per share of 37.18. EBITDA reached 18.45B, while operating income came in at 16.40B.

As of June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh holds 25.10B in cash and equivalents against 45.93B in total debt, resulting in a net debt position of 20.83B. Total book value stands at -14.90B, with working capital of -26.63B providing operational flexibility.

Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh produced 26.74B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.35B in capital expenditures, free cash flow totaled 23.39B - equivalent to 99.09 per share.

Over the twelve months ended June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh posted a gross margin of 3.84, reflecting its pricing power and cost economics. The operating margin of 1.25 and net profit margin of 0.67 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh paid dividends of 10.75 per share. The dividend payout ratio of 28.95 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.13, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh shareholders.

As of June 30, 2026, Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh has an Altman Z-Score of 6.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.